Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) Meeting Abstract
| Authors: | Pietanza, M. C.; Spigel, D.; Bauer, T. M.; Ready, N. E.; Glisson, B. S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; Strickland, D. K.; Govindan, R.; Burris, H. A.; Rudin, C. M.; Dylla, S. |
| Abstract Title: | Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) |
| Meeting Title: | 18th European Cancer Conference (ECCO 18) |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2015 Sep 25-29 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S712 |
| Language: | English |
| ACCESSION: | WOS:000361887403256 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)31931-1 |
| Notes: | Meeting Abstract: 7LBA -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work